The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BENZYLPENICILLIN KABI (Fresenius Kabi Australia Pty Ltd)
Product name
BENZYLPENICILLIN KABI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
benzylpenicillin sodium
Registration type
New generic medicine
Indication
For the treatment of infections caused by benzylpenicillin sensitive organisms. These include Streptococcus pyogenes and most other Gram-positive organisms. It is also indicated for the treatment of syphilis. Benzylpenicillin Kabi may also be used for the prevention of bacterial endocarditis in dental and upper respiratory tract procedures and prevention of wound infections and sepsis in surgical procedures where Streptococci are the likely pathogens.